Intercell completes Phase I clinical trial for an improved seasonal Influenza vaccine formulated with IC31
Intercell's strategic Flu partner Novartis to include IC31® in further clinical trials
29-Feb-2008 -
Intercell AG announced the completion of Phase I clinical trials of the companys adjuvant IC31® in combination with the seasonal, trivalent influenza vaccine Agrippal® from Novartis.
In this randomized, controlled Phase I trial, 72 individuals received one shot of either Agrippal®, or Agrippal® ...
clinical trials
immunogenicity
pharmacology
+2